# Pizarra — PT-pseudo_0615b2bd8504 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.27   (95% CI 0.02-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.26  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 0.6 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=160.0, age=63.0, psad=2.635, dre_ord=2.0, vol=60.71, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the high PSA velocity (35.73 ng/mL/yr) and the significant PSA rise from a prior value of 115.9 ng/mL to 160.0 ng/mL, which suggests a rapid progression. It also missed the context of the PI-RADS 5 score combined with the prior positive biopsy status, which strongly influences the interpretation of the current findings.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.45 +/- 0.27), indicating high uncertainty. This uncertainty is likely due to the conflict between the high csPCa probability (0.95889634) and the prior positive biopsy result. The prior cannot weigh the clinical significance of the PI-RADS 5 score in conjunction with the rapid PSA velocity and the prior positive biopsy, which might push the decision towards biopsy despite the prior's statistical leaning.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <full panel> -> <If the lab panel shows significant changes in other markers (e.g., inflammation, other cancers), it might alter the risk assessment.>
  <PSA history> -> <trend / velocity beyond the headline value> -> <A more detailed trend might confirm aggressive disease progression, strengthening the case for biopsy.>
  <radiology / mpMRI report> -> <full mpMRI prose behind the headline imaging values> -> <The detailed description of the lesion characteristics and extent is crucial for assessing the PI-RADS 5 confidence.>
  <previous GP / urology consultation notes> -> <previous notes> -> <These notes might contain clinical context regarding the initial diagnosis or follow-up plans that inform the current decision.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **MRI Report**
  Subject: Prostate Multiparametric MRI | Date: 20 January 2025 | Facility: Amsterdam UMC (AMC)
  Indication: Rising PSA (160.0 ng/mL) alongside a previously positive biopsy history.
  FINDINGS:
  Prostatic dimensions yield a total volume of 60.71 mL. A discrete abnormality resides in the left peripheral zone, spanning roughly 35 mm at its widest point. Imaging characteristics include pronounced T2 hypointensity, marked diffusion restriction paired with depressed ADC values, and prompt contrast uptake on dynamic sequences. Suspicion for extracapsular extension centers on the left posterolateral margin. No concerning osseous or nodal signals are present.
  IMPRESSION:
  PI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension. PSAD 2.635 ng/mL/mL. csPCa predicted probability 0.95889634

  **PSA History**
  {"case_id": "PT-pseudo_0615b2bd8504", "psa_trend": [{"date": "Aug 2022", "val": 14.8}, {"date": "Jun 2023", "val": 18.9}, {"date": "Apr 2024", "val": 12.0}, {"date": "Jan 2025", "val": 160.0}]}

  **Previous Notes**
  {"date": "31 May 2024", "author": "Dr. C. Peters (GP)", "text": "Initial screening captured a PSA reading of 55.0 ng/mL, while the contemporaneous digital rectal assessment showed no abnormalities. Subsequent transrectal ultrasound guidance yielded a biopsy confirming Gleason 3+4 pathology. The clinical record was then submitted to the urology department for case review."}, {"date": "06 Feb 2023", "author": "Dr. C. Peters (GP)", "text": "Subsequent tracking shows the PSA level climbing to 115.9 ng/mL. The individual reports consistent urinary complaints quantified at an IPSS of 10, with no episodes of acute retention or visible blood in the urine. Due to the accelerated PSA trajectory and established histology, an expedited outpatient urology visit was scheduled for advanced imaging and procedural planning."}

  **Laboratory Results**
  {"name": "PSA", "val": "160.0 ng/mL", "date": "11 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "16.71 ng/mL", "date": "11 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "10%", "date": "11 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "13.2 g/dL", "date": "11 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "163 x10^9/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "72 umol/L", "date": "11 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "11 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "55 U/L", "date": "11 Jan 2025", "flag": ""}, {"name": "LDH", "val": "185 U/L", "date": "11 Jan 2025", "flag": ""}}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension.
  PSA velocity of 35.73 ng/mL/yr, indicating rapid progression.
  Prior biopsy was positive.
  csPCa predicted probability of 0.95889634.
  
  AGAINST sampling this patient now:
  Prior biopsy was positive (suggesting prior diagnosis is established).

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the high-risk MRI finding (PI-RADS 5 with suspected extension) and the rapid PSA velocity, which aligns with the concerns raised by the LLM-1-GAP-ANALYST. This leans towards a recommendation for biopsy.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 5 with suspected extracapsular extension) and the rapid PSA velocity of 35.73 ng/mL/yr. This is further supported by the prior positive biopsy status and the high csPCa predicted probability of 0.95889634. The statistical prior suggested deferral, but the retrieved evidence of aggressive imaging features and rapid biochemical progression decisively tipped the recommendation toward sampling.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
